Selpercatinib | Health Canada Patents | Expiry | Expiration | Dates | PharmaCompass.com

Please Wait

Applying Filters...

Grow Your Pharma Business Digitally

Find Suppliers : API/FDF
- Search Our Integrated Database
Services
Excipients
CDMO Prospector
- Demo Dashboard
Drugs in Dev.
News
Blog
Market Place
Login

Selpercatinib
Health Canada Patents

AMI Lifesciences is Driven by Chemistry. Powered by People.

Contact Supplier

Polpharma is a Polish CDMO of APIs and a significant European API producer, delivering products to companies worldwide.

Contact Supplier

Bhavna Laboratories is an API & Intermediate manufacturer focusing on the muscle relaxant & ophthalmic segments.

Contact Supplier

Zach System is committed to providing Highly Customized Solutions for all your Development Programs.

Contact Supplier

Quotient Sciences- Molecule to Cure. Fast.

Contact Supplier

pharmacompass-2-m-2025-08-25

Selpercatinib

ACCESS ALL DATA, CHEMISTRY

ACCESS ALL DATA
Browse all information
CHEMISTRY
Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

9 API Suppliers, 1 USDMF, 4 NDC API, 5 Listed Suppliers, $ API Reference Price

9 API Suppliers
1 USDMF
4 NDC API
5 Listed Suppliers
$ API Reference Price

DEVELOPMENTS

33 Drugs in Development

33 Drugs in Development

INTERMEDIATES

1 Intermediate Suppliers

1 Intermediate Suppliers

FINISHED DOSAGE FORMULATIONS

12 FDF Dossiers, 8 FDA Orange Book, 2 Canada, 2 Australia

12 FDF Dossiers
8 FDA Orange Book
2 Canada
2 Australia

DIGITAL CONTENT

27 News #PharmaBuzz

27 News #PharmaBuzz

GLOBAL SALES INFORMATION

1 US Medicaid Prescriptions

1 US Medicaid Prescriptions

MARKET PLACE

1 APIs

1 APIs

PATENTS & EXCLUSIVITIES

88 US Patents, 68 US Exclusivities, 6 Health Canada Patents

88 US Patents
68 US Exclusivities
6 Health Canada Patents

$ API Ref.Price (USD/KG) : 15,211 Xls

Filters

Reset all filters

Filters

FILTER :

filter Company Reset all filters

6 All

01 6Gowling WLG (Canada) LLP

filter Patent Reset all filters

6 All

01 23039760

02 23079010

03 23079012

filter Product Reset all filters

6 All

01 6SELPERCATINIB

filter Dosage Reset all filters

6 All

01 6CAPSULE

filter Exp Date Reset all filters

6 All

01 22037-10-10

02 42038-10-10

Product Main Page

01

Gowling WLG (Canada) LLP

Selpercatinib

CPHI Shenzhen

Not Confirmed

Gowling WLG (Canada) LLP

Country

CPHI Shenzhen

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2037-10-10

Date Granted : 2020-09-08

Selpercatinib

Brand Name : RETEVMO

Patent Number : 3039760

Filing Date : 2017-10-10

Strength per Unit : 40mg

Dosage Form : CAPSULE

Human Or VET : Human

Route of Administration : ORAL

Patent Expiration Date : 2037-10-10

Date Granted : 2020-09-08

Portfolio PDF

Product Web Link

Virtual Booth

Digital Content

Website

Corporate PDF

02

Gowling WLG (Canada) LLP

Selpercatinib

CPHI Shenzhen

Not Confirmed

Gowling WLG (Canada) LLP

Country

CPHI Shenzhen

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2038-10-10

Date Granted : 2023-01-24

Selpercatinib

Brand Name : RETEVMO

Patent Number : 3079012

Filing Date : 2018-10-10

Strength per Unit : 40mg

Dosage Form : CAPSULE

Human Or VET : Human

Route of Administration : ORAL

Patent Expiration Date : 2038-10-10

Date Granted : 2023-01-24

Portfolio PDF

Product Web Link

Virtual Booth

Digital Content

Website

Corporate PDF

03

Gowling WLG (Canada) LLP

Selpercatinib

CPHI Shenzhen

Not Confirmed

Gowling WLG (Canada) LLP

Country

CPHI Shenzhen

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2038-10-10

Date Granted : 2023-02-28

Selpercatinib

Brand Name : RETEVMO

Patent Number : 3079010

Filing Date : 2018-10-10

Strength per Unit : 40mg

Dosage Form : CAPSULE

Human Or VET : Human

Route of Administration : ORAL

Patent Expiration Date : 2038-10-10

Date Granted : 2023-02-28

Portfolio PDF

Product Web Link

Virtual Booth

Digital Content

Website

Corporate PDF

04

Gowling WLG (Canada) LLP

Selpercatinib

CPHI Shenzhen

Not Confirmed

Gowling WLG (Canada) LLP

Country

CPHI Shenzhen

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2037-10-10

Date Granted : 2020-09-08

Selpercatinib

Brand Name : RETEVMO

Patent Number : 3039760

Filing Date : 2017-10-10

Strength per Unit : 80mg

Dosage Form : CAPSULE

Human Or VET : Human

Route of Administration : ORAL

Patent Expiration Date : 2037-10-10

Date Granted : 2020-09-08

Portfolio PDF

Product Web Link

Virtual Booth

Digital Content

Website

Corporate PDF

05

Gowling WLG (Canada) LLP

Selpercatinib

CPHI Shenzhen

Not Confirmed

Gowling WLG (Canada) LLP

Country

CPHI Shenzhen

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2038-10-10

Date Granted : 2023-01-24

Selpercatinib

Brand Name : RETEVMO

Patent Number : 3079012

Filing Date : 2018-10-10

Strength per Unit : 80mg

Dosage Form : CAPSULE

Human Or VET : Human

Route of Administration : ORAL

Patent Expiration Date : 2038-10-10

Date Granted : 2023-01-24

Portfolio PDF

Product Web Link

Virtual Booth

Digital Content

Website

Corporate PDF

06

Gowling WLG (Canada) LLP

Selpercatinib

CPHI Shenzhen

Not Confirmed

Gowling WLG (Canada) LLP

Country

CPHI Shenzhen

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2038-10-10

Date Granted : 2023-02-28

Selpercatinib

Brand Name : RETEVMO

Patent Number : 3079010

Filing Date : 2018-10-10

Strength per Unit : 80mg

Dosage Form : CAPSULE

Human Or VET : Human

Route of Administration : ORAL

Patent Expiration Date : 2038-10-10

Date Granted : 2023-02-28

Portfolio PDF

Product Web Link

Virtual Booth

Digital Content

Website

Corporate PDF

Contact us
to update this info

Privacy policy
Terms and conditions
Disclaimers
Ask Us!